Zepbound Pill: Oral Tirzepatide for Weight Loss (What We Know)
People want a pill version of Zepbound. That makes sense — Zepbound is one of the most effective weight loss drugs available, and many people prefer pills over injections. Eli Lilly is working on it. But the Zepbound pill is not available yet. Here is what we know.
Quick Answer
An oral (pill) version of tirzepatide — the drug in Zepbound and Mounjaro — is in development by Eli Lilly. Phase 3 trials are underway but the drug is not FDA-approved and not available yet. If you want a GLP-1 pill right now, Foundayo and oral semaglutide are your available options.
Why a Zepbound Pill Matters
Zepbound injections show up to 21% average weight loss. That is the strongest of any currently approved weight loss drug. But it requires a weekly shot. A pill version could:
- Remove the needle barrier for people who hate injections
- Make it easier to travel with (no refrigeration concerns)
- Be simpler for daily routines
- Expand access to people who avoid GLP-1s specifically because of injections
The Challenge: Getting Tirzepatide Into a Pill
Tirzepatide is a peptide — a large molecule. The human digestive system breaks down peptides. Getting enough tirzepatide through the stomach and into the bloodstream at therapeutic levels is hard.
This is the same challenge that semaglutide faced. Rybelsus (oral semaglutide) solved it by adding an absorption enhancer (SNAC) and requiring people to take it on an empty stomach and wait 30 minutes before eating. Foundayo solved it differently — it uses a non-peptide molecule that absorbs easily with no food restrictions.
Eli Lilly is likely working on a similar absorption-enhancer approach for oral tirzepatide. But the details are not public yet.
What Oral GLP-1 Options Are Available Now
While you wait for a Zepbound pill, these oral options exist today:
| Option | Active Drug | Weight Loss | Food Rules | Status |
|---|---|---|---|---|
| Foundayo | Orforglipron | ~11% | None | FDA-approved (Apr 2026) |
| Wegovy Pill | Semaglutide | Data still emerging | Empty stomach, wait 30 min | FDA-approved |
| Rybelsus | Semaglutide | Less data for weight | Empty stomach, wait 30 min | FDA-approved (diabetes) |
Foundayo is the newest and most convenient oral option — no food or water restrictions at all. It is not tirzepatide, so the weight loss numbers are lower than Zepbound injections. But for people who want a daily pill without hassle, it is the best current choice. CVS Caremark added Foundayo to its national formularies in May 2026, improving insurance access. Eli Lilly is also positioning low-dose Zepbound injections and Foundayo as maintenance options for patients who want to transition off higher-dose injections.
See our GLP-1 pills guide for a full comparison.
Zepbound Pill vs Foundayo: What to Know
This is the comparison more people are making now:
| Zepbound Pill (future) | Foundayo (available now) | |
|---|---|---|
| Active drug | Tirzepatide | Orforglipron |
| Mechanism | GLP-1 + GIP | GLP-1 only |
| Weight loss (injection data) | ~20% | ~11% (pill data) |
| Food rules | Unknown (likely some) | None |
| Form | Daily pill (expected) | Daily pill |
| Availability | Not yet | Available now |
The key question: will oral tirzepatide maintain the ~20% weight loss seen with injections? That depends on how well the drug absorbs through the digestive system. If absorption is good, a Zepbound pill could be significantly stronger than Foundayo. If absorption is limited, the gap may narrow.
We won't know until Phase 3 data is published.
How Oral Tirzepatide Might Compare
If approved, an oral Zepbound pill would likely:
- Be taken daily (not weekly like the injection)
- Have similar weight loss results to Zepbound injections, though possibly slightly lower
- Require some food or water restrictions (like Rybelsus), unless Eli Lilly develops a formulation similar to Foundayo's approach
- Cost in a similar range to Zepbound injections
These are educated guesses based on how other oral GLP-1s compare to their injectable versions. Nothing is confirmed until clinical trial data is published.
When Might It Be Available?
There is no confirmed FDA filing date yet. Here is what we know as of June 2026:
- Oral tirzepatide is in clinical trials (Phase 3 underway as of June 2026)
- Eli Lilly has not announced a target FDA filing date
- Eli Lilly is currently emphasizing low-dose Zepbound and Foundayo as its oral and maintenance-access strategies, while oral tirzepatide remains a longer-term pipeline play
- Drug development often takes longer than expected
- A realistic earliest approval would be 2027-2028 if trials go well
Do not wait for oral tirzepatide if you need treatment now. Effective options are available today.
What to Do in the Meantime
If you want Zepbound-level weight loss but prefer pills:
- Talk to your doctor about whether Zepbound injections might work for you — the needle is smaller than most people expect
- Consider Foundayo if you want a daily pill right now — it is the simplest oral GLP-1 option available
- Try oral semaglutide if you want the same drug family as Wegovy in pill form
- Check back here — we will update this page when oral tirzepatide news breaks
If you do start a GLP-1 injection while waiting, you will need alcohol prep pads and a sharps container for weekly injections.
GLPSpot may earn from qualifying purchases.
Bottom Line
A Zepbound pill is coming but is not here yet. Eli Lilly is developing oral tirzepatide in Phase 3 trials, and if it works, it could be the strongest oral weight loss option on the market. For now, Foundayo and oral semaglutide are your real pill options. If you need stronger weight loss, Zepbound injections remain the most effective approved drug available. In the meantime, Eli Lilly is expanding access through low-dose Zepbound and Foundayo, both of which are now covered by CVS Caremark formularies.
This article is for informational purposes only and does not constitute medical advice. Oral tirzepatide is not FDA-approved. Talk to your healthcare provider about treatment options that are right for you. Last updated: June 3, 2026.
